Eli Lilly announced positive long-term efficacy data for Omvoh (mirikizumab-mrkz) in treating Crohn's disease, with extended follow-up from the Phase 3 VIVID-2 trial revealing sustained clinical benefits through year three. The trial results showed 92.4% of patients achieved clinical remission and 91.2% maintained corticosteroid-free remission status, representing a significant proportion of the study population retaining therapeutic response over the extended treatment period.
The three-year data also highlighted meaningful reductions in serious disease complications, with Omvoh demonstrating decreased rates of hospitalizations and surgical interventions compared to placebo. These findings establish Omvoh as the only IL-23p19 inhibitor class member to date with demonstrated durable efficacy across an extended follow-up window, addressing a key clinical need in inflammatory bowel disease management where maintaining long-term remission remains challenging.
The results strengthen Omvoh's position in the competitive Crohn's disease treatment landscape and provide clinicians with long-term safety and efficacy data to inform treatment decisions. This sustained remission profile may have implications for disease management strategies and patient outcomes in moderate-to-severe Crohn's disease populations.